This week, we're again focusing on research presented at the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer Singapore, which was moved to a virtual format and held January 28 to 31, 2021, in light of the COVID-19 pandemic. We'll hear about findings in mesothelioma, small cell lung cancer, and drug development. To listen to more podcasts from ASCO, visit asco.org/podcasts . "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week...
Jul 12, 2023•14 min•Ep. 84
This week, we're hearing from two thoracic oncologists on research presented at the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer Singapore, which was moved to a virtual format and held January 28 to 31, 2021, in light of the COVID-19 pandemic. To listen to more podcasts from ASCO, visit asco.org/podcasts . "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we're hearing from two thoracic oncologists on research presente...
Jul 12, 2023•16 min•Ep. 83
This week, we'll discuss the findings of a study that examined the prevalence of KRAS G12C mutations across different populations. Then, we'll hear recent news about FDA oncology drug approvals in the month of January. Coverage of stories discussed this week on ascopost.com: Prevalence of KRAS G12C Somatic Mutations by Cancer Type, Race, and Sex FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic ALK -Positive ALCL FDA Approves Fam-Trastuzumab Deruxtecan-nx...
Jul 12, 2023•14 min•Ep. 82
This week, we're back for more coverage of the 2021 Gastrointestinal Cancers Symposium, hearing about the FIGHT trial in advanced gastric/gastroesophageal junction adenocarcinoma, the ClarIDHy study in IDH1 -mutated cholangiocarcinoma, and the POLO trial in BRCA -mutated pancreatic cancer. To listen to more podcasts from ASCO, visit asco.org/podcasts . "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we're back for more coverage of the 2021 Gastrointestinal Cancer...
Jul 12, 2023•15 min•Ep. 81
The 2021 Gastrointestinal Cancers Symposium, held in a virtual format this year, is being held this weekend, January 15th to 17th, 2021. We're discussing findings from the meeting with three study authors. To listen to more podcasts from ASCO, visit asco.org/podcasts . "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> The 2021 Gastrointestinal Cancers Symposium, held in a virtual format this year, is being held this weekend, January 15th to 17th, 2021. We're discussing findin...
Jul 12, 2023•13 min•Ep. 80
This week, we'll review a meta-analysis of several trials studying the efficacy of 3 vs 6 months of adjuvant chemotherapy for patients with advanced colon cancer. We'll also discuss a report on the frequency of osteonecrosis of the jaw among patients with metastatic bone disease treated with zoledronic acid, as well as several risk factors for the development of the condition. Coverage of stories discussed this week on ascopost.com: Final Overall Survival Results of the IDEA Collaboration: 3 vs ...
Jul 12, 2023•12 min•Ep. 79
The San Antonio Breast Cancer Symposium took place virtually from December 8 to 12th. This week, we're featuring three important studies from the meeting, focusing on a new prognostic tool; the treatment of depression and related symptoms in young breast cancer survivors; and a chemoimmunotherapy regimen for triple-negative disease. To listen to more podcasts from ASCO, visit asco.org/podcasts . "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> The San Antonio Breast Cancer S...
Jul 12, 2023•15 min•Ep. 78
This week, we'll focus further on studies presented at the 2020 ASH Annual Meeting & Exposition, including findings on the use of whole-genome sequencing to trace the origins of a blood cancer; stem cell transplant for older patients with myelodysplastic syndromes; and a triplet therapy for relapsed and refractory multiple myeloma. To listen to more podcasts from ASCO, visit asco.org/podcasts . "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we'll focus furth...
Jul 12, 2023•13 min•Ep. 77
The 2020 ASH Annual Meeting & Exposition, held in a virtual format this year, begins today. We're featuring three studies on the podcast this week from the meeting. To listen to more podcasts from ASCO, visit asco.org/podcasts . "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> The 2020 ASH Annual Meeting & Exposition, held in a virtual format this year, begins today. We're featuring three studies on the podcast this week from the meeting....
Jul 12, 2023•16 min•Ep. 76
As COVID-19 infection rates again spike around the nation, this week, we're looking at two recent studies focused on COVID-19 and cancer. The first describes the rate of infection with the virus among asymptomatic patients with cancer undergoing active treatment for their solid tumors. The second explores how the ongoing pandemic is affecting the way patients with cancer choose to participate in clinical trials. Coverage of stories discussed this week on ascopost.com: Serial COVID-19 Screening i...
Jul 12, 2023•10 min•Ep. 75
This week, we're focusing on lung cancer—first, with a report on how therapy-related adverse events experienced by patients with lung cancer treated with immunotherapy may help to predict survival outcomes; and second, with a video about disparities in certain populations when it comes to lung cancer screening and treatment. Coverage of stories discussed this week on ascopost.com: Multisystem Immune-Related Adverse Events and Disease Outcomes Among Patients With NSCLC Treated With Immunotherapy ...
Jul 12, 2023•11 min•Ep. 74
This week, we're focusing on high-impact research in prostate cancer presented during the virtual 2020 ASTRO Annual Meeting. The studies included a focus on GnRH receptor antagonist therapy; imaging-based guidance for radiotherapy intensification; and methods of radiotherapy boosts. To listen to more podcasts from ASCO, visit asco.org/podcasts . "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we're focusing on high-impact research in prostate cancer presented dur...
Jul 12, 2023•16 min•Ep. 73
This week, we'll be featuring discussions of two late-breaking abstracts presented during the virtual 2020 American Society for Radiation Oncology, or ASTRO, Annual Meeting. The first focuses on the role of imaging to plan treatment with radiotherapy in patients with prostate cancer. The second discusses strategies to manage the pain of spinal metastases. To listen to more podcasts from ASCO, visit asco.org/podcasts . "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This wee...
Jul 12, 2023•10 min•Ep. 72
This week, we'll focus on two recent approvals from the U.S. Food and Drug Administration in patients with leukemia and lymphoma, respectively. Coverage of stories discussed this week on ascopost.com: FDA Approves Venetoclax Combination Regimen for Certain Adult Patients With AML FDA Extends the Approval of Pembrolizumab for Patients With Classical Hodgkin Lymphoma To listen to more podcasts from ASCO, visit asco.org/podcasts . "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}">...
Jul 12, 2023•16 min•Ep. 71
This week, we'll review results of a trial that evaluated first-line anti–PD-L1 therapy vs platinum-based chemotherapy in patients with metastatic lung cancer and high PD-L1 expression. We'll also discuss findings from a study that evaluated whether patients receiving care for advanced cancer based on the recommendations of a molecular tumor board tended to survive longer or experience more time without disease progression. Coverage of stories discussed this week on ascopost.com: First-Line Atez...
Jul 12, 2023•13 min•Ep. 70
This week, we'll be featuring our last disease-specific roundup from the ESMO Virtual Congress 2020. We'll hear from three experts on their findings in breast cancer, focusing on results from two IMpassion trials as well as the efficacy of a novel antibody-drug conjugate in triple-negative disease, and a telehealth program for patients receiving chemotherapy. To listen to more podcasts from ASCO, visit asco.org/podcasts . "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This...
Jul 12, 2023•15 min•Ep. 69
This week, we'll be reviewing results from several reports on lung cancer presented during the ESMO Virtual Congress 2020. The findings focus on the use of radiotherapy, biomarkers, targeted treatments, and immunotherapy. To listen to more podcasts from ASCO, visit asco.org/podcasts . "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we'll be reviewing results from several reports on lung cancer presented during the ESMO Virtual Congress 2020. The findings focus on...
Jul 12, 2023•13 min•Ep. 68
This week, we're hearing about three reports on genitourinary cancers presented at ESMO Virtual Congress 2020. We'll hear directly from the researchers about first-line treatment for metastatic renal cell carcinoma, as well as the long-term results of a doublet therapy for men with advanced hormone-naive prostate cancer. To listen to more podcasts from ASCO, visit asco.org/podcasts . "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we're hearing about three report...
Jul 12, 2023•14 min•Ep. 67
This weekend, the ESMO Virtual Congress 2020 is underway, and we're sharing interviews with two authors of high-impact papers on breast cancer and head and neck cancer presented at the event. To listen to more podcasts from ASCO, visit asco.org/podcasts . "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This weekend, the ESMO Virtual Congress 2020 is underway, and we're sharing interviews with two authors of high-impact papers on breast cancer and head and neck cancer presen...
Jul 12, 2023•10 min•Ep. 66
We'll discuss the efficacy of a triplet combination therapy in BRCA -mutated, HER2-negative advanced breast cancer. Then, we'll move on to a report that detailed multiorgan immunotherapy-related adverse events in patients treated with atezolizumab. Last, we'll review the FDA's approval of the RET-targeted therapy pralsetinib in patients with metastatic RET fusion–positive non–small cell lung cancer. Coverage of stories discussed this week on ascopost.com: Addition of Veliparib to Carboplatin/Pac...
Jul 12, 2023•15 min•Ep. 65
Due to the unexpected passing of actor Chadwick Boseman on August 28, there has been a renewed interest in young-onset colorectal cancer. Mr. Boseman, known for his roles in Black Panther, Marshall , and Get on Up , was only 43 when he died from colon cancer. This week, we'll go back in The ASCO Post Podcast archives and hear from Kimmie Ng, MD, MPH, who was first on the show about a year ago, offering her insights on the rising rates of colorectal cancer in young adults. "}" data-sheets-userfor...
Jul 12, 2023•14 min•Ep. 64
This week on The ASCO Post Podcast , we'll first hear about a study of the monoclonal antibody sintilimab in combination with pemetrexed and platinum to treat advanced nonsquamous non–small cell lung cancer. Then we'll review the results of the CheckMate 743 trial, which suggest a new standard of care in first-line treatment of unresectable malignant pleural mesothelioma. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week on The ASCO Post Podcast, we'll first hear ab...
Jul 12, 2023•11 min•Ep. 63
We'll first hear about a study that found a steep decline in non–small cell lung cancer mortality from 2013 to 2016. Then, we'll close out with a review of a report on the addition of locoregional radiotherapy to chemotherapy in patients with chemotherapy-sensitive metastatic nasopharyngeal carcinoma. Coverage of stories discussed this week on ascopost.com: Study Suggests Drop in Non–Small Cell Lung Cancer Mortality Rates Due to Treatment Advances, Reduction in Incidence Addition of Locoregional...
Jul 12, 2023•10 min•Ep. 62
This week, we'll start with a follow-up analysis of pathologic complete response in patients participating in the I-SPY2 trial. Then, we'll move on to a study that sought to answer whether a longer time from diagnosis to surgical treatment lowered overall survival in women with early-stage breast cancer. Last, we'll hear about how the COVID-19 pandemic is worsening disparities in cancer care among racial and ethnic minorities and the medically underserved. Coverage of stories discussed this week...
Jul 12, 2023•16 min•Ep. 61
This week, we'll review recommendations from a new guideline issued by the American Cancer Society on cervical cancer screening. Then, we'll discuss the FDA's approval of a triplet therapy for advanced melanoma. Lastly, we'll hear a summary of a panel discussion on telehealth for patients with cancer during the COVID-19 pandemic. Coverage of stories discussed this week on ascopost.com: American Cancer Society Updates Guideline for Cervical Cancer Screening FDA Approves Atezolizumab Plus Cobimeti...
Jul 12, 2023•18 min•Ep. 60
This week, we'll discuss a study that compared two combination treatments for previously untreated patients with localized pancreatic cancer. Then, we'll explore whether a longer-established diagnosis of cancer is associated with higher risk of severe COVID-19 infection or death from the virus. Last, we'll review the FDA's recent approval of a CAR T-cell immunotherapy for patients with relapsed or refractory mantle cell lymphoma. Coverage of stories discussed this week on ascopost.com: First-Lin...
Jul 12, 2023•11 min•Ep. 59
This week, we'll discuss phase II results on cabozantinib in patients with advanced bladder cancer. Then, we'll review a study on behaviors related to COVID-19 prevention among cancer survivors. Lastly, we'll hear a discussion about the keynote lecture presented at the First International Summit on Interventional Pharmacoeconomics. Coverage of stories discussed this week on ascopost.com: Cabozantinib in Platinum-Refractory Metastatic Urothelial Carcinoma Cancer Survivors Are Adhering to COVID-19...
Jul 12, 2023•16 min•Ep. 58
This week, we'll discuss the efficacy of the combination of lenvatinib and pembrolizumab for patients with advanced gastric cancer. We'll also highlight key points from the recent USPSTF draft recommendation on CT screening for lung cancer. Finally, we'll review a regulatory approval in metastatic bladder cancer and hear from the principal investigator of the confirmatory trial. Coverage of stories discussed this week on ascopost.com: Lenvatinib Plus Pembrolizumab for Advanced Gastric Cancer USP...
Jul 12, 2023•14 min•Ep. 57
This week, we'll review two influential breast cancer studies presented during the ASCO20 Virtual Scientific Program: MINDACT and HER2CLIMB. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we'll review two influential breast cancer studies presented during the ASCO20 Virtual Scientific Program: MINDACT and HER2CLIMB.
Jul 12, 2023•12 min•Ep. 56
This week, we'll be hearing from the presenters of three abstracts focused on multiple myeloma presented during the ASCO20 Virtual Scientific Program. "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we'll be hearing from the presenters of three abstracts focused on multiple myeloma presented during the ASCO20 Virtual Scientific Program.
Jul 12, 2023•18 min•Ep. 55
